|
|
 |
|
Viewing report
|
|
|
|
The Vioxx Withdrawal: Changes and Opportunities for the Industry
Decision Resources, Inc., June 2005, Pages: 18
The safety issues that precipitated the withdrawal of Vioxx from the U.S. market have had a devastating effect on the market potential of the selective COX-2 inhibitor class and raised doubts about the safety of all nonsteroidal anti-inflammatory drugs (NSAIDs). Furthermore, the Vioxx withdrawal sparked a continuing controversy over the FDAs regulation of drugs in the United States and the pharmaceutical industrys promotion of drugs.
This report contrasts the Vioxx withdrawal with other U.S. drug withdrawals, highlighting the unusual set of circumstances surrounding the event, and examines its ramifications for the industry. We discuss potential changes to drug regulation and promotion in the United States, consider how public opinion shapes the decisions of regulators and legislators, and propose that the pharmaceutical industry become a willing and proactive partner in the reforms triggered by this unique event.
Business Implications
- The withdrawal of Vioxx from the U.S. market occurred against a backdrop of public relations disasters for the FDA, public criticism of rising drug costs, debate over Medicare reform, and increasing concern about the safety of approved drugs. The withdrawal set in motion a series of events likely to change the face of drug regulation and marketing in the United States.
- Public opinion of the pharmaceutical industry is at an all-time low. Criticism of the cost and quality of drug marketing has heightened in the wake of the Vioxx withdrawal because heavy promotion to doctors and the public is blamed for the vigorous uptake of this drug. Further, the public in the United States blames the rising cost of pharmaceuticals, in part, on what it considers excessive marketing.
- Following a long and public drug safety debate in the United States, the FDA must rebuild its reputation. The lengthy time that Vioxx remained on the market while its safety was in question and high mortality estimates have been most damaging. Public confidence in the agency has been shaken, and many commentators charge that the FDA’s short approval times undermine safety.
- The FDA has responded by introducing a series of reforms and initiatives aimed at strengthening drug safety programs and increasing the transparency of its operations. A return to slower drug approval times looks set for the future, together with more stringent postmarketing surveillance and rapid, effective response to safety concerns.
- Pharmaceutical companies need to embrace the coming changes if they are to be successful in the future. There is no question that the industry will be held more accountable for its activities, and public perception may be the key to its success.
Customers who bought this item also bought
Drug Safety in the Post-Vioxx Era: New Legislation, Regulation and Company Strategies in Europe and the US
COX-2 withdrawal - Therapeutic, R&D and pharmaceutical impact
Marketing Drugs in an Era of Pharmacovigilance - Best practice after drug safety scares and the implications for the future
Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
Why Do Drugs Fail?
Prescription Drugs - Global Strategic Business Report
COX-2 Inhibitors - Biology, Therapeutic Agents & Markets
Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies
Vioxx Recall - Revenue Analysis and Impact on Cox-2 Inhibitor Markets
Commercial Insight: Osteoarthritis - Market Sees Steady Growth
Event Analysis and Response Service: Cox-2s - Cox-2 Crisis Dents Big Pharma Confidence
2005 News in Review: Important Changes for the Pharmaceutical
|
|
|
|
